Quick Answer
| What actually changed | What did not change |
|---|---|
| An FDA advisory committee voted in July 2026 to recommend BPC-157, TB-500, and MOTS-c (plus KPV, Semax and Epitalon) for the 503A Bulks List | None of them are on the 503A Bulks List yet |
| On October 28, 2026, HHS announced a draft policy letting licensed 503A pharmacies compound all six by prescription, under strict conditions | None of them is an FDA-approved drug |
| Patients now have a regulated, prescription-only route to these six peptides | Research use only products are still not legal for human use |
The July 2026 PCAC Vote
The FDA's Pharmacy Compounding Advisory Committee (PCAC) met over two days, July 23 and 24, 2026, to review bulk drug substances nominated for inclusion on the Section 503A Bulk Drug Substances List. That list matters because a substance has to be on it, have its own U.S. Pharmacopoeia monograph, or be a component of an FDA-approved drug, before a compounding pharmacy can legally prepare it under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Seven peptides were on the agenda. BPC-157, KPV, TB-500, and MOTS-c were reviewed on the first day. Emideltide, the substance name used in this process for DSIP, along with Semax and Epitalon, were reviewed on the second day.
What Was Recommended
The committee voted to recommend six of the seven peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide (DSIP) was the one substance the committee did not recommend. The margins were narrow, which reflects a genuinely split committee rather than a clear consensus.
| Peptide | Use Under Review | Reported Vote |
|---|---|---|
| BPC-157 | Ulcerative colitis | 8 to 6, 1 abstention (recommended) |
| TB-500 | Wound healing | 8 to 6, 1 abstention (recommended) |
| KPV | Wound healing, inflammatory conditions | 8 to 6, 1 abstention (recommended) |
| MOTS-c | Obesity, osteoporosis | 7 to 5, 2 abstentions (recommended) |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | 8 to 5, 1 abstention (recommended) |
| Epitalon | Insomnia | 7 to 4, 1 abstention (recommended) |
| Emideltide (DSIP) | Opioid withdrawal, insomnia, narcolepsy | 6 to 7, 1 abstention (not recommended) |
Worth knowing: multiple outlets covering the vote also reported that a majority of the committee members who voted in favor had industry ties to the peptide or compounding space, and that FDA's own staff scientists had reportedly recommended against inclusion before the vote. Neither of those facts changes what the vote legally means, but they're part of the full picture of how contested this recommendation was.
What This Vote Does NOT Mean
This is the part that gets lost in headlines. A PCAC recommendation is nonbinding. The FDA is not required to follow it, and as of October 30, 2026, the FDA has not adopted it through rulemaking. For any of these peptides to be permanently added to the Section 503A Bulks List, one of two things would need to happen: the FDA would need to complete a formal notice-and-comment rulemaking process, which includes publishing a proposed rule, taking public comments, and then issuing a final rule, or Congress would need to amend the underlying statute directly. Neither path is quick, and neither is guaranteed to result in the same outcome as the committee's recommendation.
It's also worth separating two different kinds of legal status that are easy to conflate. Being added to the 503A Bulks List would make it legal for a licensed compounding pharmacy to prepare a substance under specific conditions. That is not the same thing as FDA drug approval, which requires the substance to go through the full clinical trial process the FDA uses to evaluate a new drug's safety and effectiveness. Even in the best case for compounding advocates, none of these peptides would suddenly become an FDA-approved medication as a result of this process.
Why the Vote Matters Anyway
Even as a nonbinding recommendation, this vote is a meaningful signal. It puts the question of these peptides' regulatory future on the public record in a way it wasn't before. Whichever direction the FDA ultimately goes, this meeting is likely to be referenced as the starting point of that decision, which is part of why it's worth understanding clearly rather than assuming either "now it's legal" or "nothing happened."
Where Things Stand in October 2026
The big change came on October 28, 2026. The U.S. Department of Health and Human Services announced a draft enforcement discretion policy for 503A compounding using six peptide bulk drug substances: BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon, the same six the committee recommended. HHS published it in the Federal Register on October 30, 2026 (FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496). It was published as a draft: it is nonbinding, HHS can revise or withdraw it, and public comments are open for two weeks after publication, until about November 13, 2026. In plain terms, HHS says it does not intend to take action against licensed 503A pharmacies that compound these peptides for individual patients with a prescription, as long as they meet the policy's conditions, while FDA completes rulemaking (Frier Levitt summary).
| Peptide | Routes covered |
|---|---|
| BPC-157 | Subcutaneous, intramuscular, oral, topical |
| TB-500 | Subcutaneous, intramuscular |
| MOTS-c | Subcutaneous, intramuscular |
| KPV | Topical, oral |
| Semax | Intranasal |
| Epitalon | Subcutaneous, intramuscular, in intermittent courses |
The conditions are strict. Each product may contain only one of these peptides, so a BPC-157 and TB-500 blend is not covered. The ingredient must come from an FDA-registered manufacturer following current good manufacturing practice, with the facility named on its certificate of analysis, and it must be fully tested for identity, purity, potency, impurities and endotoxins. Products must be patient-specific, labeled "This is a compounded drug product. Not for resale.", and serious adverse events must be reported to FDA's MedWatch program. The policy also sets conditions on documenting how well oral products are absorbed and on which delivery devices can be packaged with a product.
Three cautions still apply. This is not FDA approval. It does not add these peptides to the 503A Bulks List, which still requires a proposed rule, public comment and a final rule, expected to take roughly 12 to 24 months. And it does not cover 503B outsourcing facilities or research use only sellers; it is non-binding and HHS can revise or withdraw it. As of October 30, 2026, the 503A Bulks List in 21 CFR 216.23 is unchanged.
Separately, FDA says its committee will meet again before the end of February 2027 to review five more substances: LL-37 (cathelicidin), GHK-Cu, dihexa acetate, Melanotan II, and PEG-MGF.
What Happens Next
The realistic next steps are on the FDA's timeline, not a fixed date. The agency could open a formal rulemaking process, which would include a public comment period before any final rule takes effect. It could also decline to act on the recommendation, or take a partial approach, and it retains its normal enforcement authority against compounding pharmacies in the meantime regardless of what the committee recommended. Anyone tracking this closely should watch for two things: any changes to the HHS draft policy after its public comment period, and a Federal Register proposed rule adding these peptides to the 503A Bulks List. To understand the practical steps for patients, see How to Get Peptides Legally.
For the current regulatory status of each individual peptide, including compounds not part of this specific July 2026 vote, see the FDA Peptide Status Tracker.
Related Reading
For background on how the 503A framework works in general, see What Is FDA's 503A Bulks List?. For what a compounded peptide actually is and how it differs from a manufactured research chemical, see What Is a Compounded Peptide?. For the underlying human evidence picture on these specific compounds, independent of their regulatory status, see BPC-157 Human Studies, TB-500 Human Studies, and MOTS-c Human Studies. For TB-500's core compound reference, see TB-500: Dosing, Mechanism and Regulatory Status.
Frequently Asked Questions
Is BPC-157 legal now because of the 2026 FDA vote?
Partly. The July 2026 committee vote itself was nonbinding, but on October 28, 2026, HHS announced a draft enforcement discretion policy that lets licensed 503A pharmacies compound BPC-157 for individual patients with a prescription, under strict sourcing, testing and labeling conditions. BPC-157 is still not FDA-approved, is not yet on the 503A Bulks List, and research use only BPC-157 is still not legal for human use.
What exactly did the FDA advisory committee vote on in July 2026?
The Pharmacy Compounding Advisory Committee (PCAC) met July 23 to 24, 2026, to review seven peptides nominated for the Section 503A Bulk Drug Substances List: BPC-157, KPV, TB-500, and MOTS-c on the first day, and Emideltide (DSIP), Semax, and Epitalon on the second. The committee voted to recommend six of the seven, with only Emideltide voted down.
Why is this vote significant if it isn't legally binding?
PCAC recommendations carry real weight even though the FDA isn't required to follow them, because they're often reported as a signal of where the agency's regulatory posture is heading. In this case, the votes were narrow and reportedly went against internal opposition from FDA staff scientists, which made it notable news on its own rather than a routine procedural step.
Does this vote mean TB-500 and MOTS-c are now FDA-approved drugs?
No. Inclusion on the 503A Bulks List and FDA drug approval are two different things. Being on the 503A list would only mean a compounding pharmacy could legally prepare the substance under specific conditions. It would not mean the substance went through the clinical trial process the FDA requires for a new drug approval, and it would not mean insurance would cover it.
What would have to happen next for these peptides to actually become legal to compound?
The FDA would need to either complete a formal notice-and-comment rulemaking process, which includes a proposed rule, a public comment period, and a final rule, or Congress would need to amend the underlying statute. Neither of those had happened as of October 30, 2026. In the meantime, a draft HHS policy announced October 28, 2026 lets licensed 503A pharmacies compound the six recommended peptides by prescription, under strict conditions.
Is there a draft policy that allows compounding BPC-157?
Yes. On October 28, 2026, HHS announced a draft enforcement discretion policy covering BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon. Licensed 503A pharmacies can compound them for individual patients with a prescription, using a single ingredient from an FDA-registered CGMP manufacturer, with full testing, approved routes, a compounded drug label and adverse event reporting. It is not FDA approval and does not cover 503B facilities or research chemical sellers.
What were the exact PCAC vote counts in July 2026?
As reported by Reuters and McDermott Will & Schulte: BPC-157, TB-500, and KPV were each recommended 8 to 6 with one abstention; MOTS-c 7 to 5 with two abstentions; Semax 8 to 5 with one abstention; and Epitalon 7 to 4 with one abstention. Emideltide (DSIP) was not recommended, 6 to 7 with one abstention. FDA has not posted an official tally.